Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012

BACKGROUND: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare cancers. In order to provide more insights in drugs for rare neoplastic disorders...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Orphanet J Rare Dis
Auteurs principaux: Pauwels, Kim, Huys, Isabelle, Casteels, Minne, Larsson, Kristina, Voltz, Caroline, Penttila, Karri, Morel, Thomas, Simoens, Steven
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5314481/
https://ncbi.nlm.nih.gov/pubmed/28209180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-017-0578-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires